Oragenics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Oragenics, Inc. on April 12, 2010. The filing discloses the execution of a Distribution Agreement with RicciPharma, a health products company based in Rome and Slovakia. The agreement covers the distribution of Oragenics' proprietary oral care probiotic products, EvoraPlus and EvoraKids.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity figures. This report focuses on a contractual event rather than periodic financial results.
Material Changes and Agreement Details
- Distribution Scope: RicciPharma will exclusively distribute products to the Vatican's healthcare foundation (Duc in Altum), various United Nations agencies (UNESCO, UNICEF, WHO, FAO) in Africa, Asia, South America, and the Caribbean, as well as specific medical associations in Slovakia and Italy.
- Geographic Reach: Distribution extends to independent pharmacies in Belarus, the Baltic States, Romania, Albania, Russia, and Poland.
- Payment Terms: Orders must be paid in advance of shipment. Pricing may be adjusted with sixty days' notice.
- Minimum Purchase Requirements: RicciPharma must meet minimum purchase thresholds to maintain exclusivity. Failure to meet these requirements allows Oragenics to terminate the agreement.
- Term and Termination: The initial term is twenty months, subject to extension. Oragenics may terminate for any reason with thirty days' written notice. Either party may terminate for breach if not cured within thirty days.
Outlook, Risks, and Contingencies
Management notes that there can be no assurance that RicciPharma will purchase the minimum required quantities or maintain the exclusivity provided in the Agreement. The agreement includes a contingency for termination if minimum purchase requirements are not met. RicciPharma is required to maintain suitable general liability and product liability insurance.
Key Facts for Investor Verification
- Verify the financial stability and distribution capabilities of RicciPharma.
- Monitor whether minimum purchase requirements are met to ensure the agreement remains active.
- Confirm the actual volume of orders placed under the advance payment terms.
- Assess the regulatory environment for probiotic products in the specified international territories.